Dynamic path analysis - a useful tool to investigate mediation processes in clinical survival trials

被引:12
|
作者
Strohmaier, Susanne [1 ]
Roysland, Kjetil [1 ]
Hoff, Rune [1 ]
Borgan, Ornulf [2 ]
Pedersen, Terje R. [3 ]
Aalen, Odd O. [1 ]
机构
[1] Univ Oslo, Oslo Ctr Biostat & Epidemiol, Dept Biostat, N-0317 Oslo, Norway
[2] Univ Oslo, Dept Math, N-0317 Oslo, Norway
[3] Univ Oslo, Ulleval Hosp, N-0317 Oslo, Norway
关键词
additive hazard regression; directed acyclic graphs; direct effect; IDEAL study; indirect effect; mediation analysis; survival analysis; MYOCARDIAL-INFARCTION; APOLIPOPROTEIN-B; END-POINTS; CHOLESTEROL; EVENTS; RISK;
D O I
10.1002/sim.6598
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
When it comes to clinical survival trials, regulatory restrictions usually require the application of methods that solely utilize baseline covariates and the intention-to-treat principle. Thereby, much potentially useful information is lost, as collection of time-to-event data often goes hand in hand with collection of information on biomarkers and other internal time-dependent covariates. However, there are tools to incorporate information from repeated measurements in a useful manner that can help to shed more light on the underlying treatment mechanisms. We consider dynamic path analysis, a model for mediation analysis in the presence of a time-to-event outcome and time-dependent covariates to investigate direct and indirect effects in a study of different lipid-lowering treatments in patients with previous myocardial infarctions. Further, we address the question whether survival in itself may produce associations between the treatment and the mediator in dynamic path analysis and give an argument that because of linearity of the assumed additive hazard model, this is not the case. We further elaborate on our view that, when studying mediation, we are actually dealing with underlying processes rather than single variables measured only once during the study period. This becomes apparent in results from various models applied to the study of lipid-lowering treatments as well as our additionally conducted simulation study, where we clearly observe that discarding information on repeated measurements can lead to potentially erroneous conclusions. Copyright (c) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:3866 / 3887
页数:22
相关论文
共 50 条
  • [21] Survival analysis in clinical trials: Old tools or new techniques
    Paoletti, Xavier
    Asselain, Bernard
    [J]. SURGICAL ONCOLOGY-OXFORD, 2010, 19 (02): : 55 - 58
  • [22] SEQUENTIAL-ANALYSIS OF SURVIVAL TIMES IN CLINICAL-TRIALS
    OLSCHEWSKI, M
    SCHUMACHER, M
    [J]. BIOMETRICAL JOURNAL, 1986, 28 (03) : 273 - 293
  • [23] Survival analysis in clinical trials: Past developments and future directions
    Fleming, TR
    Lin, DY
    [J]. BIOMETRICS, 2000, 56 (04) : 971 - 983
  • [24] Applications of survival analysis in clinical trials involving both eyes
    Maguire, MG
    VanNatta, M
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1996, 37 (03) : 1998 - 1998
  • [25] Propofol and survival: a meta-analysis of randomized clinical trials
    Pasin, L.
    Landoni, G.
    Cabrini, L.
    Borghi, G.
    Taddeo, D.
    Saleh, O.
    Greco, T.
    Monti, G.
    Chiesa, R.
    Zangrillo, A.
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2015, 59 (01) : 17 - 24
  • [26] EVALUATION OF ARTHRITIS CLINICAL-TRIALS USING SURVIVAL ANALYSIS
    READING, JC
    EGGER, MJ
    WARD, JR
    WILLIAMS, HJ
    COLEMAN, ML
    [J]. CONTROLLED CLINICAL TRIALS, 1982, 3 (02): : 154 - 155
  • [27] Exploring mechanisms of action in clinical trials of complex surgical interventions using mediation analysis
    Sharples, Linda
    Papachristofi, Olympia
    Rex, Saleema
    Landau, Sabine
    [J]. CLINICAL TRIALS, 2020, 17 (06) : 654 - 663
  • [28] LIMITING DILUTION ANALYSIS OF HUMAN T-CELLS - A USEFUL CLINICAL TOOL
    SHARROCK, CEM
    KAMINSKI, E
    MAN, S
    [J]. IMMUNOLOGY TODAY, 1990, 11 (08): : 281 - 286
  • [29] Diagnostic Meta-Analysis: A Useful Tool for Clinical Decision-Making
    Ahmed, S. Ejaz
    [J]. TECHNOMETRICS, 2020, 62 (02) : 289 - 289
  • [30] Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials
    Krois, Wilfried
    Romar, Alexander Ken
    Wild, Thomas
    Dubsky, Peter
    Exner, Ruth
    Panhofer, Peter
    Jakesz, Raimund
    Gnant, Michael
    Fitzal, Florian
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 164 (02) : 421 - 427